Achillion Pharmaceuticals (NASDAQ:ACHN) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Achillion Pharmaceuticals (NASDAQ:ACHN) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.02, Fidelity Earnings reports.

Achillion Pharmaceuticals stock opened at $6.36 on Friday. The company has a market cap of $888.45 million, a P/E ratio of -12.47 and a beta of 1.67. Achillion Pharmaceuticals has a 1-year low of $1.29 and a 1-year high of $6.46. The company has a fifty day simple moving average of $4.93 and a 200 day simple moving average of $3.79.

Several equities research analysts have recently issued reports on ACHN shares. Zacks Investment Research downgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating and set a $4.75 price objective for the company. in a research report on Tuesday, August 27th. Svb Leerink downgraded shares of Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating and increased their price objective for the stock from $5.00 to $6.30 in a research report on Friday, October 18th. JMP Securities downgraded shares of Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday. Leerink Swann downgraded shares of Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.30 price objective for the company. in a research report on Friday, October 18th. Finally, ValuEngine raised shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 16th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $4.96.

In related news, CEO Joseph Truitt sold 133,484 shares of the firm’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $6.37, for a total value of $850,293.08. Following the completion of the transaction, the chief executive officer now owns 103,734 shares of the company’s stock, valued at $660,785.58. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.58% of the stock is currently owned by company insiders.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

Recommended Story: Elliott Wave Theory

Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.